Tauopathies, including Alzheimer's disease (AD) and other neurodegenerative conditions, are defined by a pathological hallmark: neurofibrillary tangles (NFTs). NFT accumulation is thought to be closely linked to cognitive decline in AD. Here, we perform a genomewide association study for NFT pathologic burden and report the association of the PTPRD locus (rs560380, P = 3.8 × 10 − 8 ) in 909 prospective autopsies. The association is replicated in an independent data set of 369 autopsies. The association of PTPRD with NFT is not dependent on the accumulation of amyloid pathology. In contrast, we found that the ZCWPW1 AD susceptibility variant influences NFT accumulation and that this effect is mediated by an accumulation of amyloid β plaques. We also performed complementary analyses to identify common pathways that influence multiple neuropathologies that coexist with NFT and found suggestive evidence that certain loci may influence multiple different neuropathological traits, including tau, amyloid β plaques, vascular injury and Lewy bodies. Overall, these analyses offer an evaluation of genetic susceptibility to NFT, a common end point for multiple different pathologic processes.
INTRODUCTION
Multiple neurologic diseases can lead to loss of cognitive function with older age. Several of them can be grouped by neuropathologic changes found at autopsy, such as neurofibrillary degeneration, which is best characterized by the accumulation of neurofibrillary tangles (NFTs). 'Tauopathies' share the accumulation of aggregates consisting of the microtubule-associated protein tau (Tau) but have different clinical manifestations and distinct etiologies that ultimately converge in the abnormal accumulation of Tau species. Tauopathies include neurodegenerative disorders such as Alzheimer's disease (AD), some forms of frontotemporal degeneration, progressive supranuclear palsy and corticobasal degeneration, as well as forms of neurodegeneration occurring secondary to environmental insults, such as in chronic traumatic encephalopathy. 1 In an older population, it is possible that multiple different disease mechanisms interact to lead to the accumulation of NFT. Identifying risk factors that contribute to the accumulation of pathologic Tau is therefore meaningful, not just for the vast majority of the population that is at risk for AD but even more broadly for informing our understanding of other tauopathies.
Here, we leverage neuropathologic data collected from two longitudinal cohorts of aging whose participants are nondemented at the time of enrollment; in both the Religious Order Study (ROS) and the Rush Memory and Aging Project (MAP), brain donation is a condition of enrollment. Importantly, these subjects represent a sample of the older population in which multiple different neuropathologic changes are present, including NFT but also amyloid β plaques, vascular injury, Lewy bodies and other pathologic changes. We focused on factors that influence NFT accumulation from all central nervous system (CNS) insults commonly experienced by older subjects. Thus, in our discovery study, we performed a quantitative trait analysis to identify susceptibility loci for NFT and replicated our main result in an independent longitudinal cohort study of aging that collects neuropathologic data.
In individuals selected as AD cases or AD controls, a recent genome-wide association study (GWAS) 2 sought genetic factors associated with multiple individual neuropathologies, using correlations in β-estimates to discuss shared effects across the various pathologies. In this paper we propose a different approach. We leverage the data collected on multiple pathologies within each individual in the ROS and MAP studies to identify loci that display pleiotropic effects on multiple pathologies within the same individual and thus influence multiple insults and pathways leading to neurodegeneration. Such loci could be excellent targets of further investigation both in understanding Tau pathology and in exploring the shared pathways leading to the CNS's response to different disease processes.
MATERIALS AND METHODS Participants
The subjects consisted of participants from two longitudinal cohort studies operated out of the Rush Alzheimer's Disease Center in Chicago, the ROS and the MAP. All participants are required to sign an informed consent and an Anatomical Gift Act at enrollment, agreeing to donate their brains (ROS) or brains, spinal cords, and select nerves and muscles (MAP) to the study upon death. Both studies were approved by the Institutional Review Board of Rush University Medical Center.
The ROS and MAP studies are maintained and the data are collected by a single group of researchers at the Rush Alzheimer's Disease Center. Data collectors in both studies are cross-trained to allow efficient merging of data and all analyses are performed on the two cohorts combined. A more comprehensive description of the ROS and MAP studies can be found in previous publications. 3, 4 At the time of analysis there were over 1200 deceased participants combined in the ROS and MAP cohorts. Of these, 909 were successfully genotyped, all of whom had non-missing values for all seven pleiotropic phenotypes and covariates: neuritic plaque (NP), NFTs, diffuse plaque (DP), amyloid angiopathy, micro-and macroinfarct, and Lewy bodies, age at death and sex.
The Adult Changes in Thought (ACT) cohort, used for replication in this analysis, is a community-based study of brain aging and dementia, which collects data on neuropathology on a subsample of their participants' post mortem. Participants in ACT are aged 65 years or older at enrollment, randomly sampled from a multicenter health maintenance organization from King County, Washington. More detailed information on the ACT cohort is published elsewhere [5] [6] [7] 
Pathological phenotypes
The neuropathological phenotypes analyzed included NP, NFTs, DP, presence of Lewy bodies, microscopic and gross (macroscopic) infarcts and cerebral amyloid angiopathy (CAA).
For ROS and MAP, brain removal was performed at either Rush University or at one of 12 designated sites across the country and sent to the Rush Alzheimer's Disease Center where all post-mortem data collection occurred. Detailed descriptions of the autopsy procedure are published elsewhere. [8] [9] [10] [11] In brief, NPs, DPs and NFTs were observed with a modified Bielschowsky silver stain and counted in five regions of the brain: midfrontal, temporal, inferior parietal, entorhinal and hippocampus. For each measure in each region, counts were normalized by dividing by the standard deviation, and a z-score of the counts within each region was calculated. For the global measure of each AD pathology, we averaged these scores over the five regions, followed by a square root transformation that allowed us to treat it as a normally distributed continuous variable. 12 CAA was evaluated in four neocortical regions of the brain: midfrontal, midtemporal, angular and calcatrine cortices. Three monoclonal anti-human β-amyloid antibodies with the following dilutions were used for the assessment: (1) 6F/3D (1:50; Dako North America, Carpinteria, CA, USA), (2) 10D5 (1:600; Elan Pharmaceuticals, San Francisco, CA, USA) and (3) 4G8 (1:9000; Covance Labs, Madison, WI, USA). A score for β-amyloid deposition ranging from 0 (no deposition) to 4 (circumferential deposition in over 75% of vessels in the total region) was determined from meningeal and parenchymal vessels in each region separately, with the final score for the region defined as the maximum score between meningeal and parenchymal CAA scores. Finally, a final CAA score was created using the average score across the four regions in each individual and classified as none, mild, moderate and severe using consistent thresholds determined by the neuropathologist. 13 Lewy bodies present in either the nigra or cortex was defined using consensus guidelines established by the international consortium on dementia with Lewy bodies. 14 Details of microscopic and macroscopic infarct measurements are detailed in the previous literature. 15 Briefly, all suspected or visualized gross infarcts were further dissected for histological confirmation. Microscopic infarct measures were taken from examination of a minimum of nine regions in one hemisphere. Both macroscopic and microscopic infarcts were analyzed as binary, presence in at least one region or absence in all regions. Braak staging was performed according to consensus criteria for ROS, MAP and ACT cohorts, 16, 17 with detailed methods reported in previously published literature. 9, 18 Genotyping. DNA used for genotyping ROS and MAP participants was collected from post-mortem brain tissue, whole blood or lymphocytes. The final QCed data set that consisted of 1709 participants were genotyped on the Affymetrix GeneChip 6.0 Platform (Santa Clara, CA, USA) at the Broad Institute's Center for Genotyping or the Translational Genomics Research Institute and 384 were genotyped on the Illumina OmniQuad Express platform at Children's Hospital of Philadelphia, of these 799 and 110, respectively, had pathology information and were included in these analyses. The EIGENSTRAT software (https://www.hsph.harvard.edu/alkesprice/software/) was used to calculate principal components used to control for population substructure and analysis was limited to only those of European decent. 19 All DNA samples go through the same rigorous quality control process before and after genotype generation, and we see no difference in data quality based on source of DNA. Further information regarding genotyping and imputation can be found in previous publications. 20, 21 RNA-Seq expression data were generated from frozen dorsolateral prefrontal cortex tissues following the construction of complementary DNA libraries. The paired-end reads were mapped using the Ensemble human genome transcriptomic database (http://www.ensembl.org). RNA expression of the associated AD genes was queried and examined for an association with AD pathologies. Details on the RNA-Seq expression profiling are provided in the Supplementary Methods.
Statistical analysis
We used t-tests and χ 2 tests to compare ROS and MAP participants on demographic characteristics and pathological traits For each of the continuous pathological phenotypes (NP, DP and NFT), we performed univariate GWAS using linear regression in PLINK. We analyzed dichotomous outcomes (Lewy body dementia and micro-and macroinfarctions) in PLINK with logistic regression. We used R to analyze an ordinal CAA outcome (http://www.r-project.org) using ordered logistic regression with the function polr from the package MASS (https://cran. r-project.org/web/packages/MASS/MASS.pdf). 22 To minimize artifacts of imputation, we analyzed samples from the Affymetrix and Illumina platforms independently and then meta-analyzed the findings using a fixed-effects method weighting by the inverse of the standard error. We used PLINK to meta-analyze the continuous and dichotomous phenotypes, and METAL to meta-analyze CAA. 23 For the cis-expression quantitative trait analysis, we used linear regression to assess the association between significant loci from the NFT analyses and mRNA expression within 1 Mb of the analyzed single-nucleotide polymorphism (SNP).
We used the mPhen function in the R package MultiPhen 2.0 to perform the pleiotropic GWAS. 24 MultiPhen performs an inverted ordered logistic regression with SNP as the outcome and the phenotypes and covariates as the independent variables. The value for SNP used in mPhen is the dosage rounded to its nearest integer 0, 1 or 2. A χ 2 test statistic is calculated from the comparison of two models with a likelihood ratio test: one model containing all pleiotropic phenotypes plus covariates against a second model containing only covariates. The P-value is based on the resulting χ 2 statistic, where the number of pleiotropic phenotypes equals the number of degrees of freedom.
In the pleiotropy GWAS, we pooled the data and adjusted for platform within the regression. As the pathological phenotypes are associated with age at death and sex, all eight GWASes (seven univariate and one pleiotropic), were adjusted for age at death, sex, cohort (ROS or MAP) and the first three principal components to account for population substructure. 25 
RESULTS
Discovery study for susceptibility to NFT accumulation Characteristics of the participants (n = 909 with full data), including means (s.d.) and frequency (%) of the pathology measures are reported in Table 1 . The results of the primary analysis, a GWAS for NFT burden, are presented in Table 2 . As expected, we found that the APOE locus on chromosome 19 is the top result, consistent with prior studies in this cohort 8 and studies in other populations. 2, 26 The Q-Q and Manhattan plots for the GWAS of NFT burden are presented in Supplementary Figures S1 and S2.
Outside APOE, we found a SNP, rs560380, that exceeds a threshold of genome-wide significance in an intron of PTPRD (P = 3.1 x 10 − 8 ) ( Figure 1 ). The variance explained by the PTPRD locus is 3%, which is second only to the APOE locus (rs429358) at 9% in terms of contribution to overall variation in NFT burden. We were able to replicate this result (with the same direction of effect) in an independent data set generated from participants in the ACT study, a longitudinal study of older participants who are nondemented at enrollment. ACT participants do not have the same quantitative NFT measure, but we found P = 0.02 for association with the n = 380 participants (46% male and average age at death of 87.2 years (s.d. = 6.4)) with a complementary phenotype of the same pathology: Braak stage, a semiquantitative rating scale based on the topographic progression of NFT. For completeness, we also evaluated the Braak stage in ROS and MAP participants in a secondary analysis, and we found that rs560380 is also associated with the Braak phenotype. Using an ordinal logistic regression analysis, we see consistency across the three studies (ROS: β = 0.31, P = 0.0099; MAP: β = 0.41, P = 0.0002; ACT: β = 0.30, P = 0.021, β for each additional 'A' (major) allele): together, the three sets of subjects have a meta-analyzed P-value of 5.3 × 10 − 7 . As expected, the quantitative NFT burden and Braak stage are strongly correlated (Spearman's r = 0.867) in the ROS and MAP cohorts. Having replicated evidence of association between a variant and NFT, we initiated additional analyses to investigate possible mechanisms of the association.
Besides NFT accumulation, many other neuropathologic traits are assessed in ROS and MAP, which we used to further characterize the impact of the PTPRD locus. rs560380 had a nominal association with NP (β = 0.07, P = 0.005). NP are the form of amyloid β plaques most closely associated with AD dementia, and the co-occurrence of NP and NFT neuropathologically characterizes AD. We found that rs560380 was nominally associated with a pathologic diagnosis of AD (OR = 1.27, 95% confidence interval (CI) (1.04, 1.55), P = 0.018). As amyloid β accumulation is thought to precede the accumulation of NFT in the context of AD, 27 we evaluated whether the PTPRD association with NFT was driven by this specific pathophysiologic process. We first performed a mediation analysis that compares a model without NP to one with NP included as a covariate. In the basic model, rs560380 has a β of 0.10 (P = 3.8 × 10 − 8 ) for the association with NFT, and, in the model that also includes NP, we see a β of 0.07 (P = 1 × 10 − 6 ), a reduction of 33% of the effect size of the SNP. This indicates partial mediation of the SNP's effect by NP accumulation; however, the majority of the SNP's effect is not mediated through NP. Results are similar when using measures of amyloid β and Tau pathology derived from immunohistochemistry as previously reported for APOE 28 (data not shown). Consistent with the effect of the PTPRD locus being due to more than one pathophysiologic process, we found that rs560380 remains associated with NFT burden in the absence of NP: in the subset of 132 participants with no NP on neuropathologic examination, we found a β of 0.06 (P = 0.02), which is similar to the SNP's effect size (β = 0.07) in the analysis adjusting for NP ( Figure 2 ).
We also found modest evidence that rs560380 is associated with other neuropathologic traits: rs560380 is weakly associated with CAA (P = 0.002), a form of amyloid β vasculopathy. We repeated these analyses adjusting for APOE ϵ4 burden and with the exception of the APOE haplotype, we found no meaningful change in effect sizes or P-values. ( Supplementary Table 1) We assessed whether the rs560380 variant influences mRNA expression in RNA sequence data available from the dorsolateral prefrontal cortex of 494 ROS and MAP participants, a subset of our data set. We did not find evidence that rs560380 or the single SNP in LD (rs324543, R 2 4 0.5) had an effect on either the level of PTPRD expression or the abundance of its different isoforms in our sample (data not shown). As these data are generated from cerebral cortical samples, they do not exclude the possibility that the SNP has effects elsewhere in the CNS: as with many susceptibility variants, 29 its effect may be cell-or context-specific and is simply not appreciated in this particular location and mixture of cells. Further, given that many AD susceptibility alleles influence gene expression in myeloid cells, we also checked the expression quantitative trait results generated from healthy participants of the ImmVar project, 29 but we found that the rs560380 variant has no effect on mRNA expression of PTPRD in ex vivo monocytes or naïve CD4+ T cells. As is standard in cis-expression quantitative trait analyses, we examined the expression of all other genes within a 1 Mb radius of the SNP, but PTPRD is the only gene found in this genomic segment. Thus, rs560380 does not appear to influence mRNA expression of PTPRD in the samples that we have queried to date, and, as is the case for a majority of disease-associated SNPs, 29 its mechanism of action remains unclear
Leveraging correlated neuropathologic traits to enhance gene discovery for NFT As the participants in the ROS and MAP data sets have information on a wealth of different but related neuropathologic phenotypes, we chose to pursue a complementary strategy for further gene discovery: we implemented a secondary analysis for pleiotropy to identify variants that affect not only NFT but also other neuropathologies. Such pleiotropic effects are likely in the context of neurodegeneration in which different insults may ultimately trigger similar responses in neurons and other CNS cells.
We first calculated a correlation matrix between seven neuropathologic outcomes that are available in almost all of our participants. Results are presented in Supplementary Table 2 , showing, as expected, modest to strong correlations between findings, ranging from ρ = 0.41 (P o 0.001) between NFT and diffuse amyloid plaques (DP) to 0.69 (P o0.001) between NP and DP. Lewy body pathology was not correlated (ρ o 0.1) (ps40.05) with the other traits, and the two neurovascular pathology traits (microscopic and macroscopic strokes) showed only weak (ρ = 0.25, P o0.001) correlation with each other. Thus, the observed level of correlation, while substantial in certain cases, remains within the range in which a pleiotropic analysis can be considered: a prior study showed that, even in the presence of correlations as high as 0.9, the MULTIPHEN method shows no inflation in the type I error. 24 We therefore used MULTIPHEN to implement a pleiotropy analysis integrating results from association studies of seven neuropathologic traits (see details in the Supplementary Methods section). The APOE locus serves as a positive control since it is known to influence several of these traits. 30 Results are presented in Table 3 ; Q-Q and Manhattan plots for the MULTIPHEN GWAS are presented in Supplementary Figures S3 and S4 . Overall, the most Table 3 ). Looking at the top non-APOE results that are not significant but have a P o 1 × 10 − 5 in the pleiotropy analysis, we note a few interesting results. First, there are a few examples where a SNP such as rs12597858, near the HS3ST4 gene, has a modest association with NFT burden (P = 0.0039) in the primary analysis and a much stronger pleiotropy score (P = 9.5 × 10 − 6 ) ( Table 3) that is driven by a broad effect on five of the remaining six neuropathologic traits: NP burden (P = 0.003), DP burden (P = 0.03), Lewy bodies (P = 0.03), CAA (P = 0.03) and macroscopic infarcts (P = 0.0003) (Figure 3 ). HS3ST4 encodes a protein involved in heparan sulfate biosynthesis. Notably, heparan sulfate proteoglycans have been implicated in many different biological and pathologic processes, including AD and the cellular propagation of both Tau and α-synuclein pathologies. [31] [32] [33] Another example of a SNP whose effect becomes appreciable only when considering multiple neuropathologic traits is in the POLD3 gene: the top SNP, rs4145953, has a modest effect on NFT burden (P = 2.4 × 10 − 4 ) and a stronger pleiotropic score (P = 1.1 × 10 − 6 ) ( Table 3) , which is driven by additional, modest associations with NP burden (P = 1.1 × 10 − 4 ), DP burden (P = 2.7 × 10 − 5 ) and macroscopic infarcts (P = 0.01).
As compared with HS3ST4 whose pleiotropic association is driven by a modest effect on many neuropathologies, a second type of locus, like PTPRD, has a strong effect on one trait and modest effects on two other traits: NP (P = 0.005) and CAA (P = 0.002). Thus, not surprisingly, this SNP is suggestive but not significant in the pleiotropy analysis (P = 9.7 × 10 − 6 ), with this association being driven primarily by the NFT trait. In another example, SNP chr3:197 113 961 in the SLC29A4 gene is nearly significant genome wide in the pleiotropic analysis (P = 6.6 × 10 − 8 ) and is driven by effects on microscopic (P = 3.4 × 10 − 6 ) and macroscopic (P = 9.3 × 10 − 4 ) infarcts. However, this variant has no effects on non-vascular traits.
Tables with the top results for the GWAS for all the neuropathologies examined are presented in Supplementary  Tables S4-S9 , and Q-Q plots and Manhattan plots for each trait are presented in Supplementary Figures S5-S16.
Role of known disease-associated variants in NFT accumulation and pleiotropy
We also evaluated more closely the role of SNPs known to be associated with tauopathies (AD and progressive supranuclear palsy). 26, 34 Results are displayed in Table 4 . In the 24 susceptibility loci that we evaluate, [34] [35] [36] [37] we found a significant NFT association (using a significance cutoff of 0.002 = 0.05/24) with the rs1476679 SNP in the ZCWPW1 locus (β = 0.07, P = 4.9x10 − 4 ) ( Table 4 ). As with the PTPRD variant, rs1476679 also influences NP (P = 0.0043), and, when we adjust for NP, the β of the NFT association (β = 0.037, P = 0.024) was reduced by 47%. Thus, in this case, much of the SNP's effect appears to be mediated through pathologic processes that underlie NP. The only other locus to show some level of suggestive association with NFT in our data is rs10948363, a SNP in the CD2AP gene (P = 0.0085), consistent with a recent report and our earlier results. 2, 38 Since both ZCWPW1 and CD2AP are known AD susceptibility loci, we tested if this association is mediated through NFT pathology. In our data only the ZCWPW1 SNP (rs1476679) is associated with AD risk (β = 0.32, P = 0.003), and the effect is attenuated 50% with the addition of NFT (β = 0.15, P = 0.23). No SNPs in CD2AP were associated with AD risk in our limited data set.
DISCUSSION
Our primary analysis reports a significant association between the PTPRD locus and the accumulation of NFT in older participants. While the detailed molecular mechanism of this association remains unclear at present, we found that the effect of the rs560380 SNP on NFT accumulation is not dependent on a single pathophysiologic process. NP mediates part of the SNP's effect on NFT, but most of the effect is independent of NP, and the association is observed in individuals without substantial amyloid β pathology. This pattern of findings suggests that rs560380 may be a locus that influences the CNS's response to different insults that can lead to neuronal dysfunction and neurodegeneration.
PTPRD is a large gene that has previously been associated with restless leg syndrome [39] [40] [41] and, less convincingly, obsessive compulsive disorder. 42 The SNPs driving these associations are not found on the same susceptibility haplotype as the NFTassociated PTPRD variant and suggest the presence of allelic heterogeneity and phenotypic heterogeneity: PTPRD is implicated in NFT accumulation as well as neurologic disorders without Tau pathology. The SNPs associated with obsessive compulsive disorder and restless leg syndrome-two conditions that are not tauopathies-do not display an association with NFT burden in our data (data not shown). In terms of tauopathies, an existing PSP GWAS does not provide evidence of significant association with PTPRD. In terms of AD, a suggestive association of PTPRD with AD dementia susceptibility has been reported previously (P = 4.5 × 10 − 5 ) 37 in one AD GWAS, and in our own data, we see a modest association with AD dementia susceptibility (P = 0.04, with clinical diagnosis of AD dementia). Overall, further studies are needed to evaluate the extent of the role of this locus to clinical manifestations associated with the accumulation of NFT. Our evidence to date highlights a role for PTPRD in the accumulation of this pathologic feature, irrespective of its clinical manifestations.
PTPRD encodes the protein tyrosine phosphatase receptor-type delta protein, which is reported to have protein tyrosine phosphatase activity in vitro. 43 It is expressed in the brain where it has been implicated in synaptic differentiation. 44 A null allele in mice leads to memory impairment and altered electrophysiological responses in the hippocampus. 45 Further, in our prior work, PTPRD was considered among other AD candidate genes for studies using a Drosophila model, and knockdown of lar, the fly orthologue of PTPRD, was discovered to enhance Tau-induced retinal degeneration, consistent with its association with NFT accumulation in humans. 46 Further work in flies and other model systems is now necessary to delineate the molecular consequences of perturbations in PTPRD expression that lead to Tau pathology.
Aside from PTPRD, we note that the validated AD susceptibility ZCWPW1 allele has a significant effect on NFT accumulation ( Figure 2 ). However, unlike PTPRD, the effect of this variant appears to be mediated more strongly through an effect on amyloid β accumulation.
The other locus that deserves some discussion is HS3ST4, which had a modest effect of NFT burden but a strongly suggestive association in the pleiotropy analysis because of its effect on six of the seven available neuropathologic measures. This association was also supported by our earlier work in Drosophila: the homolog of another gene encoding a heparan sulfate biosynthetic enzyme, HS6ST3, influenced Tau toxcity in a Drosophila transgenic model. 47 This result is consistent with the emerging potential role of heparan sulfate proteoglycans as receptors for the spread of Tau and synuclein pathologies. 48 Notably, variants at loci encoding other heparan sulfate sulfotranferases have been strongly suggested in AD (HS3ST1, rs448799, P = 6.6 × 10 − 8 ) 34 as well as a study of memory performance in non-demented individuals (HS3ST4, rs11074779 P = 3.1 × 10 − 8 ). 49 Comparing our study to the recently published GWAS of multiple neuropathologies, 2 we showed similar findings with the APOE region being associated with the NFT, NP and CAA outcomes plus a strong pleiotropic association; however, we were unable to replicate their novel findings. This discordance can be explained by the multiple differences between the two studies, especially differences in phenotype definitions and sample selection as our subjects come from prospective studies of aging and are not recruited in specialty-specific dementia clinics.
Our study of older participants has certain limitations, including the fact that participants are non-demented at study entry, biasing us toward a population of older individuals who have survived to an advanced age without dementia. On the other hand, we have the advantage of performing all autopsies using a single structured protocol at a single site, minimizing the phenotypic error. In contrast to the recent study that also performed a GWAS for NFT by repurposing genotypes generated for an AD study, 2 our participants were not originally selected to fit certain clinicopathologic criteria. Since such a selection of AD 'cases' and 'controls' will influence the distribution of pathology and may limit the generalizability of its results, it was not pursued here. These features and the moderate sample sizes used in this study and the earlier NFT GWAS of AD cases and controls 26 could explain differences in the results of the two studies. However, we do have similar findings with the APOE region: we found it to be associated with the NFT, NP and CAA outcomes, but we were unable to replicate the novel finding of association with Lewy bodies. We note that the present study has high internal validity as follow-up rates exceeded 95% and autopsy rates exceeded 90% and the limited power due to small sample size should not detract from the positive results that meet reasonable thresholds of statistical significance.
In sum, this NFT GWAS begins to uncover genetic variation that influences the accumulation of Tau pathology in older individuals. In addition, we present evidence supporting the utility of a pleiotropic analysis approach in identifying genetic variation with shared effects in common brain pathologies. These two approaches-focused and pleiotropic-are complementary and will both be necessary to dissect the complex web of inter-related factors that lead impaired cognition and, ultimately, dementing syndromes.
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